Zhang Cheng-Yu, Yue Dong-Jie, Wang Di, Wu Fei-Fei
Department of Endocrinology and Metabolism, The Fifth People's Hospital of Chongqing, Chongqing, China.
Zhengzhou Second People's Hospital, Zhengzhou City, Henan Province, China.
Front Pharmacol. 2024 Jul 29;15:1346168. doi: 10.3389/fphar.2024.1346168. eCollection 2024.
To investigate the effects of tetragonum tablets and Jin Gui Ren Qi Pill on intestinal flora and metabolism in patients with diabetic kidney disease.
In the study conducted at Heping Hospital of Changzhi Medical College from March 2021 to December 2022, 30 cases of patients diagnosed with diabetic nephropathy were meticulously selected as study subjects. Employing a double-blind randomized table method, these patients were randomly allocated into three groups: the control group (n = 10), the tetragonum tablets group (n = 10), and the Jin Gui Ren Qi Pill group (n = 10). The control group received standard western medical treatments for diabetic nephropathy, including serum glucose, blood lipids, blood pressure management, and other conventional therapies. In addition to the standard treatments, the tetragonum tablets group received tetragonum tablets, while the Jin Gui Ren Qi Pill group received Jin Gui Ren Qi Pill. Before and after a 4-week treatment period, various baseline parameters were assessed, including fasting blood glucose, 2-h postprandial blood glucose, triglycerides, serum total cholesterol, serum low-density lipoprotein cholesterol, serum high-density lipoprotein cholesterol, random urine microalbumin/creatinine ratio (ACR), blood creatinine (SCr), and traditional Chinese medicine evidence scores. Stool specimens were collected from all three groups before and after treatment for 16S rDNA high-throughput sequencing, followed by comprehensive analyses including OUT clustering, Alpha diversity, Beta diversity, species composition analysis, LEfSe analysis, and KEGG function prediction. Spearman correlation analysis was employed to explore the relationship between intestinal flora and clinical indicators. Furthermore, fasting peripheral venous blood was collected from patients in the Bifidobacterium tetrapunctate tablets group and the control group before and after intervention to measure the optical density values of tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and interleukin-6 (IL-6) using the Beijing Biolite ELISA kit. This study was conducted with the approval of the Ethics Committee of Changzhi Medical College.
The combination of Jin Gui Ren Qi Pill with western medical treatment exhibited superior efficacy in ameliorating clinical symptoms and reducing the ACR in patients with DKD compared to western medical treatment alone. Furthermore, this combination therapy led to an increase in the abundance of Prevotella_7 within the intestinal flora of patients, suggesting a potential enhancement in carbohydrate metabolism by the intestinal microbiota. On the other hand, tetragonum tablets bacterial tablets combined with western medical treatment demonstrated enhanced efficacy in reducing TC levels in DKD patients compared to western medical treatment alone. Additionally, this combination therapy effectively reduced the levels of IL-2 in DKD patients, thus mitigating inflammation in these individuals.
探讨复方四君子片和金匮肾气丸对糖尿病肾病患者肠道菌群及代谢的影响。
在长治医学院和平医院于2021年3月至2022年12月开展的研究中,精心选取30例确诊为糖尿病肾病的患者作为研究对象。采用双盲随机表法,将这些患者随机分为三组:对照组(n = 10)、复方四君子片组(n = 10)和金匮肾气丸组(n = 10)。对照组接受糖尿病肾病的标准西医治疗,包括血糖、血脂、血压管理及其他常规疗法。除标准治疗外,复方四君子片组服用复方四君子片,金匮肾气丸组服用金匮肾气丸。在4周治疗期前后,评估各项基线参数,包括空腹血糖、餐后2小时血糖、甘油三酯、血清总胆固醇、血清低密度脂蛋白胆固醇、血清高密度脂蛋白胆固醇、随机尿微量白蛋白/肌酐比值(ACR)、血肌酐(SCr)以及中医证候评分。收集三组治疗前后的粪便标本进行16S rDNA高通量测序,随后进行包括OUT聚类、Alpha多样性、Beta多样性、物种组成分析、LEfSe分析和KEGG功能预测的综合分析。采用Spearman相关性分析探讨肠道菌群与临床指标之间的关系。此外,在双歧杆菌四联片组和对照组干预前后采集空腹外周静脉血,使用北京博奥联免疫吸附测定试剂盒测量肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)和白细胞介素-6(IL-6)的光密度值。本研究经长治医学院伦理委员会批准。
与单纯西医治疗相比,金匮肾气丸联合西医治疗在改善DKD患者临床症状和降低ACR方面显示出更好的疗效。此外,这种联合治疗导致患者肠道菌群中普雷沃氏菌_7丰度增加,提示肠道微生物群对碳水化合物代谢的潜在增强作用。另一方面,复方四君子片联合西医治疗与单纯西医治疗相比,在降低DKD患者总胆固醇水平方面显示出增强的疗效。此外,这种联合治疗有效降低了DKD患者的IL-2水平,从而减轻了这些个体的炎症。